On 10 January Pharmos Corporation announced that its clinical phase III trial of dexanabinol for severe traumatic brain injury has commenced inEURope. Approximately 40 centres inEURope and 30 in the U.S. are expected to participate in the study.EURopean countries participating in the study include Finland, France, Germany, the Netherlands, Italy, Spain, Belgium and the U.K., along with Israel.
I paesiEURopei che partecipano allo studio includono la Finlandia, la Francia, la Germania, i Paesi bassi, l'Italia, la Spagna, il Belgio e la Gran Bretagna insieme ad Israele.